Form 8-K

8-K — Quoin Pharmaceuticals Ltd.

Accession: 0001104659-26-117080

Filed: 2026-10-20

Period: 2026-10-20

CIK: 0001671502

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2627720d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2627720d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2627720d1_8k.htm · Sequence: 1

false

0001671502

2026-10-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported):

October 20, 2026

QUOIN

PHARMACEUTICALS LTD.

(Translation of registrant’s name into English)

State of Israel

001-37846

92-2593104

(State or other jurisdiction

of incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

42127 Pleasant Forest Court

Ashburn, VA

20148-7349

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including

area code: (703) 980-4182

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

American Depositary Shares, each

representing Thirty-five (35) Ordinary

Shares, no par value per share

QNRX

The Nasdaq Stock Market LLC

Ordinary Shares, no par value per share*

N/A

* Not for trading, but only in connection with the registration of the American Depositary Shares pursuant

to requirements of the Securities and Exchange Commission.

Indicate by check

mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this

chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01. Regulation

FD Disclosure.

On October 20, 2026,

Quoin Pharmaceuticals Ltd. (the “Company” or “Quoin”) issued a press release announcing the publication of a peer-reviewed

manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric

Compassionate-Use Case Report” in Dermatology and Therapy.. A copy of the press release is attached as Exhibit 99.1 to this

Current Report on Form 8-K (the “Report”) and is incorporated by reference herein.

The information in this

Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed to be “filed” with the Securities and

Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)

or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On October 20, 2026,

the Company announced the publication of a peer-reviewed manuscript titled “An Investigational Mechanism-Informed Therapy for Netherton

Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use Case Report” in Dermatology and Therapy. The peer-reviewed paper

introduces QRX003, the Company’s investigational topical serine protease inhibitor lotion, and describes its mechanism of action

in Netherton Syndrome. It also presents a case report from Professor Alan Irvine, consultant dermatologist at Children’s Health

Ireland and professor of dermatology at Trinity College Dublin, describing his positive clinical experience treating a pediatric patient

with QRX003 under Quoin’s Pediatric Compassionate Use Program

The case report describes

a pediatric patient with genetically confirmed Netherton Syndrome treated with once-daily, whole-body application of QRX003 on a compassionate-use

basis, added to the patient’s existing treatment plan. After six weeks, the patient’s Investigator’s Global Assessment

(IGA) score improved from 4 (severe) at baseline to 1 (almost clear), and itch, as measured by the Worst Itch Numeric Rating Scale (WI-NRS),

was reduced from 5 to 1. By eight months, IGA was 0 (clear) and WI-NRS was 0 (no itch). Over 21 months of treatment, the patient remained

mostly at IGA 0, with occasional episodes recorded at IGA 1. During the treatment period, the patient discontinued previously required

medications, including antihistamines, glucocorticoids and antivirals, has not required antibiotics since whole-body application began,

and is experiencing no sleep disturbances related to Netherton Syndrome. No adverse events considered treatment-related were reported

by the family or treating physician. The case represents the first use of QRX003 in a pediatric patient and the longest continuous exposure

to QRX003 to date.

The authors note that

these single-patient observations are consistent with a possible treatment-associated effect, and that ongoing clinical trials will further

evaluate the safety and efficacy of QRX003.

Separately, in August

Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome. In

the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint

of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215). Quoin expects to

complete recruitment of all 20 participants in CL-QRX003-004 by the end of 2026 and report topline data in the second quarter of 2027.

Item 9.01. Financial

Statements and Exhibits.

(d)

Exhibits.

The following exhibits

are filed or furnished, as applicable, with this Report:

Exhibit

Number

Description

99.1

Press Release of the Company, dated October 20, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto

duly authorized.

Date: October 20, 2026

QUOIN PHARMACEUTICALS LTD.

By:

/s/ Michael Myers

Name:

Dr. Michael Myers

Title:

Chief Executive Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2627720d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Quoin Pharmaceuticals

Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

– Peer-Reviewed

Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published

– Case

Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient

– Patient’s

Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch)

– After

21 Months of Treatment with QRX003, Patient’s Skin Remains Fully Clear and Pruritus Free

– No Adverse

Events have Been Reported for the Patient

– Full

Recruitment in Ongoing Phase 2/3 Netherton Syndrome Study Expected to Complete by End of 2026, with Topline Data Expected in Q2 2027

ASHBURN, Va., October 20,

2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage

specialty pharmaceutical company focused on rare and orphan diseases, today announced the publication of a peer-reviewed manuscript titled

“An Investigational Mechanism-Informed Therapy for Netherton Syndrome: Introduction to QRX003 and a Pediatric Compassionate-Use

Case Report” in Dermatology and Therapy. The paper was published online on October 13, 2026, is open access, and is available

at: https://doi.org/10.1007/s13555-026-01948-y

The peer-reviewed

paper introduces QRX003, the Company’s investigational topical serine protease inhibitor lotion, and describes its mechanism of

action in Netherton Syndrome. It also presents a case report from Professor Alan Irvine, consultant dermatologist at Children’s

Health Ireland and professor of dermatology at Trinity College Dublin, describing his positive clinical experience treating a pediatric

patient with QRX003 under Quoin’s Pediatric Compassionate Use Program.

The case report

describes a pediatric patient with genetically confirmed Netherton Syndrome treated with once-daily, whole-body application of QRX003

on a compassionate-use basis, added to the patient’s existing treatment plan. After six weeks, the patient’s Investigator’s

Global Assessment (IGA) score improved from 4 (severe) at baseline to 1 (almost clear), and itch, as measured by the Worst Itch Numeric

Rating Scale (WI-NRS), was reduced from 5 to 1. By eight months, IGA was 0 (clear) and WI-NRS was 0 (no itch). Over 21 months of treatment,

the patient remained mostly at IGA 0, with occasional episodes recorded at IGA 1. During the treatment period, the patient discontinued

previously required medications, including antihistamines, glucocorticoids and antivirals, has not required antibiotics since whole-body

application began, and is experiencing no sleep disturbances related to Netherton Syndrome. No adverse events considered treatment-related

were reported by the family or treating physician. The case represents the first use of QRX003 in a pediatric patient and the longest

continuous exposure to QRX003 to date.

The authors note

that these single-patient observations are consistent with a possible treatment-associated effect, and that ongoing clinical trials will

further evaluate the safety and efficacy of QRX003.

Separately, in

August Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome.

In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint

of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215). Quoin expects to

complete recruitment of all 20 participants in CL-QRX003-004 by the end of 2026 and report topline data in the second quarter of 2027.

“Publication

of this paper makes the scientific rationale behind QRX003, and Professor Irvine’s clinical experience with it, available to the

broader dermatology and Netherton communities. Netherton Syndrome remains unfamiliar to many physicians, and peer-reviewed evidence such

as this plays an important role in building awareness of the disease and of new approaches to treating it,” said Dr. Michael Myers,

Chief Executive Officer and Co-Founder of Quoin Pharmaceuticals. “We are grateful to the patient and family for allowing this experience

to be shared. This case report adds to a growing body of clinical evidence for QRX003, from our pediatric compassionate use program to

the positive interim results from our ongoing Phase 2/3 study. We look forward to completing recruitment in that study by the end of

this year.”

About Netherton Syndrome

Netherton Syndrome

is a rare, serious genetic skin disease caused by mutations in the SPINK5 gene. The condition is characterized by impaired skin barrier

function, persistent inflammation, and increased serine protease activity in the skin. There are currently no approved therapies in the

United States indicated specifically for Netherton Syndrome.

About QRX003

QRX003 is an investigational

topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has

been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug

Designation in the European Union and Japan. QRX003 lotion (4%) is currently being evaluated in whole-body clinical trials in patients

with Netherton Syndrome, including the Phase 2/3 study CL-QRX003-004.

About

Quoin Pharmaceuticals Ltd.

Quoin

Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic

products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities,

and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have

the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar

Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations,

Angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.

Cautionary Note Regarding Forward

Looking Statements

The Company cautions

that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing

future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,”

“anticipate,” “look forward,” “believe,” “may,” and “will,” among others.

This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections,

beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation,

statements relating to: ongoing clinical trials further evaluating the safety and efficacy of QRX003; the timing of completing participant

recruitment and reporting topline data for the Company’s ongoing Phase 2/3 Netherton Syndrome study; publication of the aforementioned

paper making the scientific rationale and clinical experience associated with QRX003 available to the broader dermatology and Netherton

communities; and the role of peer-reviewed evidence in building awareness of Netherton Syndrome and its treatment; and Quoin’s

belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including

Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex,

microcystic lymphatic malformations, venous malformations, angiofibromas and others.

Because such statements

are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking

statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may

never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated

in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s

ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product

candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve

desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year

ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue

reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation

to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as

may be required by law.

For further information, contact:

Quoin Pharmaceuticals Ltd.

Dr. Michael Myers, Ph.D., CEO

mmyers@quoinpharma.com

Investor Relations

PCG Advisory

Jeff Ramson

jramson@pcgadvisory.com

(646) 863-6341

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Oct. 20, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Oct. 20, 2026

Entity File Number

001-37846

Entity Registrant Name

QUOIN

PHARMACEUTICALS LTD.

Entity Central Index Key

0001671502

Entity Tax Identification Number

92-2593104

Entity Incorporation, State or Country Code

Entity Address, Address Line One

42127 Pleasant Forest Court

Entity Address, City or Town

Ashburn

Entity Address, State or Province

Entity Address, Postal Zip Code

20148-7349

City Area Code

703

Local Phone Number

980-4182

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

American Depositary Shares, each

representing Thirty-five (35) Ordinary

Shares, no par value per share

Trading Symbol

QNRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration